All In Biotech

Drug Trial Radar · NCT05867251

Study of AVZO-021 in Patients With Advanced Solid Tumors

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

430

Planned (sponsor's estimate)

Start

Aug 30, 2023

Primary completion

Jan 31, 2028

Study completion Jan 31, 2030

Sponsor

Lead sponsor
Avenzo Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).

Conditions

  • Advanced Solid Tumor
  • HR+/HER2- Breast Cancer
  • HR+, HER2-, Advanced Breast Cancer
  • CCNE1 Amplification
  • Epithelial Ovarian Cancer
  • Primary Peritoneal Cancer
  • Fallopian Tube Cancer
  • Endometrial Cancer
  • TNBC - Triple-Negative Breast Cancer

Interventions

  • AVZO-021Drug

    AVZO-021 is a selective and potent oral inhibitor of CDK2 being developed for the treatment of patients with advanced solid tumors with CDK2 dependency (1A), CCNE1 amplified solid tumors (2A), HR+/HER2- BC (1B1-1B5, 2B1-2B5) and CCNE1 amplified EOC (1C, 2C)

  • PalbociclibDrug

    Antineoplastic agent, cyclin-dependent kinase 4/6 inhibitor

  • FulvestrantDrug

    Antineoplastic agent, estrogen receptor antagonist

  • LetrozoleDrug

    Antineoplastic agent, aromatase inhibitor

  • RibociclibDrug

    Antineoplastic CDK4/6 inhibitor

  • AbemaciclibDrug

    Antineoplastic CDK4/6 inhibitor

  • CarboplatinDrug

    Alkylating agent

  • Sacituzumab Govitecan-hziyDrug

    Trop-2 antibody and topoisomerase inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1)Time frame: 28 Days
  2. Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1)Time frame: Approximately 22 months
  3. Determination of Recommended Phase 2 Dose (RP2D) (Phase 1)Time frame: Approximately 16 months
  4. Objective Response Rate (ORR) (Phase 2)Time frame: Approximately 52 months
  5. Progression Free Survival (PFS) (Phase 2)Time frame: Approximately 52 months
  6. Overall Survival (OS) (Phase 2)Time frame: Approximately 76 months
  7. Duration of response (DOR) (Phase 2)Time frame: Approximately 52 months

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • Avenzo Therapeutics Recruiting Site

    New Haven, Connecticut · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Sarasota, Florida · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Tampa, Florida · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Mineola, New York · Recruiting

  • Avenzo Therapeutics Recruiting Site

    New York, New York · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Cleveland, Ohio · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Oklahoma City, Oklahoma · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Portland, Oregon · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Philadelphia, Pennsylvania · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Dallas, Texas · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Fairfax, Virginia · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Macquarie University, New South Wales, Australia · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Wollongong, New South Wales, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.